Nilotinib
- Generic Name
- Nilotinib
- Brand Names
- Tasigna, Nilotinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C28H22F3N7O
- CAS Number
- 641571-10-0
- Unique Ingredient Identifier
- F41401512X
- Background
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), anoth...
- Indication
For the potential treatment of various leukemias, including chronic myeloid leukemia (CML).
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Chronic Phase Chronic Myeloid Leukemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Refractory Gastrointestinal stromal tumor
- Associated Therapies
- -
Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- First Posted Date
- 2013-03-07
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 34
- Registration Number
- NCT01806571
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia
- First Posted Date
- 2013-03-05
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- University of Liverpool
- Target Recruit Count
- 168
- Registration Number
- NCT01804985
- Locations
- 🇬🇧
University of Liveprool, Liverpool, United Kingdom
Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
- Conditions
- Interventions
- First Posted Date
- 2013-01-24
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 31
- Registration Number
- NCT01774630
- Locations
- 🇫🇷
Centre Hospitalier Lyon Sud, Service Hématologie, Pierre Benite, France
🇫🇷CHU de Toulouse, Service d'Hématologie, Toulouse, France
🇫🇷Centre Hospitalier de Versailles - Hôpital André Mignot - Service de Médecine B, Le Chesnay, France
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2012-12-18
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT01751425
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation
- First Posted Date
- 2012-12-07
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 59
- Registration Number
- NCT01744665
- Locations
- 🇺🇸
Compassionate Care Research Group Inc CCCMG, Fountain Valley, California, United States
🇺🇸Michigan State University / Breslin Cancer Center Breslin Cancer Center (3), Lansing, Michigan, United States
🇺🇸Hackensack University Medical Center John Theurer Cancer Center, Hackensack, New Jersey, United States
A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.
- Conditions
- Interventions
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 620
- Registration Number
- NCT01743989
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 57
- Registration Number
- NCT01735955
- Locations
- 🇬🇧
Novartis Investigative Site, Newcastle upon Tyne, United Kingdom
Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
- Conditions
- Interventions
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2021-01-05
- Target Recruit Count
- 11
- Registration Number
- NCT01702064
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 163
- Registration Number
- NCT01698905
- Locations
- 🇺🇸
USC Kenneth Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Indiana Blood and Marrow Institute, Beech Grove, Indiana, United States
🇺🇸St Agnes Hospital, Baltimore, Maryland, United States
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2012-08-21
- Last Posted Date
- 2015-10-30
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT01670084
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.